Researchers are conducting a clinical trial to evaluate RE104, a novel psychedelic drug similar to 'magic mushrooms,' as a ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...

Sage’s board wrote in late January that the offer “significantly undervalues” the company, which is currently working with Biogen towards commercializing ZURZUVAE, the first and only oral ...

Coverage: Greater than 95% of commercial and Medicaid lives covered or with a path to coverage for ZURZUVAE. Sage Therapeutics Inc (NASDAQ:SAGE) reported early commercial success with ZURZUVAE ...

Sage is focused on the goal of establishing ZURZUVAE as the standard of care for women with postpartum depression (PPD). The current commercialization investment plan includes joint sales force ...

Sage sued in response to enforce a “standstill” agreement with Biogen, which co-markets Sage’s postpartum depression drug Zurzuvae and owns about 10% of the company. While Sage’s board ...

“We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we ...

“We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we ...